EUVIMEDEUVIMED entdecken
Crossref

Subclass‐Specific Impact of β 1 ‐Adrenergic Receptor Autoantibodies and Phenotype‐Specific Interaction With β‐Blockers in a Contemporary Population With Heart Failure

Akane Kawai iD, Yuji Nagatomo iD, Midori Iwashita, Nao Morita, Ayami Naito iD, Ryota Nakazawa, Akira Taruoka, Asako Takefuji, Risako Yasuda iD, Takao Konishi iD, Yukinori Ikegami, Takumi Toya iD und 6 weitere

Journal of the American Heart Association · 2026

DOI: 10.1161/jaha.125.047402 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, 2026. Verfasst von Akane Kawai und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology National Defense Medical College Tokorozawa Japan. Hauptthemen laut MEDLINE: Receptors, Adrenergic, beta-1, Autoantibodies, Heart Failure, Adrenergic beta-Antagonists. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The clinical significance of β 1 AR‐AAb (β 1 ‐adrenergic receptor autoantibody) subclasses, particularly IgG3 (immunoglobulin G subclass 3), in contemporary populations with HF (heart failure) remain unclear, especially in relation to β‐blocker therapy and HF phenotype.

Methods

In this single‐center prospective cohort study, we enrolled 408 consecutive patients hospitalized for acute decompensated HF. β 1 AR‐AAbs and IgG subclasses were measured using enzyme‐linked immunosorbent assay. Patients were classified into IgG3‐positive, non‐IgG3‐positive, and negative groups. The primary end point was all‐cause mortality within 2 years, and the secondary end point was a composite of all‐cause death and HF rehospitalization. Multivariable Cox hazards models were used to assess associations, adjusting for clinical covariates, with subgroup analyses by HF phenotype (HF with reduced ejection fraction versus HF with preserved ejection fraction) and β‐blocker use at discharge. Results β 1 AR‐AAbs were detected in 34% of patients, with similar prevalence across HF phenotypes. IgG3‐β 1 AR‐AAb positivity was associated with higher in‐hospital mortality (11%) and increased risk of all‐cause death (adjusted hazard ratio [HR], 2.13 [95% CI, 1.14–3.99], P =0.018) and the composite end point (HR, 1.94 [95% CI, 1.19–3.14], P =0.008). These associations were observed primarily in patients not receiving β‐blockers at discharge, with significant interaction between IgG3‐β 1 AR‐AAb and β‐blocker use. Exploratory analyses suggested that these associations were more apparent in HF with preserved ejection fraction.

Conclusions

IgG3‐β 1 AR‐AAb positivity was associated with adverse outcomes in acute HF, particularly among patients not treated with β‐blockers. These findings suggest a potential role of IgG3‐β 1 AR‐AAb as a treatment‐responsive biomarker, although prospective studies are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Adrenergic, beta-1AutoantibodiesHeart FailureAdrenergic beta-AntagonistsImmunoglobulin GHumansFemaleMaleProspective StudiesPhenotypeAgedStroke VolumeHospital MortalityMiddle AgedProportional Hazards ModelsRisk FactorsEnzyme-Linked Immunosorbent AssayAged, 80 and over

Stichwörter der Autor:innen

HFpEFautoantibodyheart failureβ1 adrenergic receptorβ‐blocker

Substanzen

Receptors, Adrenergic, beta-1AutoantibodiesAdrenergic beta-AntagonistsImmunoglobulin GADRB1 protein, human

Autor:innen und Institutionen

  • Department of Cardiology National Defense Medical College Tokorozawa Japan.
  • Department of Intensive Care National Defense Medical College Tokorozawa Japan.
  • Department of Clinical Laboratory National Defense Medical College Tokorozawa Japan.
  • Division of Health Management, Department of General Practice Tokai University School of Medicine Isehara Japan.
  • Sakakibara Heart Institute Tokyo Japan.
  • Department of Cardiovascular Medicine Heart Vascular and Thoracic Institute, Cleveland Clinic Cleveland OH USA.

ORCID-Profile: Akane Kawai, Yuji Nagatomo, Ayami Naito, Risako Yasuda, Takao Konishi, Takumi Toya, Nobuyuki Masaki, Yasuo Ido, W H Wilson Tang, Takeshi Adachi

Zitieren

APA

Kawai, A., Nagatomo, Y., Iwashita, M., Morita, N., Naito, A., Nakazawa, R., Taruoka, A., Takefuji, A., Yasuda, R., Konishi, T., Ikegami, Y., Toya, T., Masaki, N., Ido, Y., Baba, A., Yoshikawa, T., Tang, W. H. W., & Adachi, T. (2026). Subclass‐Specific Impact of β 1 ‐Adrenergic Receptor Autoantibodies and Phenotype‐Specific Interaction With β‐Blockers in a Contemporary Population With Heart Failure. Journal of the American Heart Association. https://doi.org/10.1161/jaha.125.047402

Vancouver

Kawai A, Nagatomo Y, Iwashita M, Morita N, Naito A, Nakazawa R, et al. Subclass‐Specific Impact of β 1 ‐Adrenergic Receptor Autoantibodies and Phenotype‐Specific Interaction With β‐Blockers in a Contemporary Population With Heart Failure. Journal of the American Heart Association. 2026. doi:10.1161/jaha.125.047402

BibTeX
@article{Kawai2026,
  author = {Kawai, Akane and Nagatomo, Yuji and Iwashita, Midori and Morita, Nao and Naito, Ayami and Nakazawa, Ryota and Taruoka, Akira and Takefuji, Asako and Yasuda, Risako and Konishi, Takao and Ikegami, Yukinori and Toya, Takumi and Masaki, Nobuyuki and Ido, Yasuo and Baba, Akiyasu and Yoshikawa, Tsutomu and Tang, W H Wilson and Adachi, Takeshi},
  title = {Subclass‐Specific Impact of β 1 ‐Adrenergic Receptor Autoantibodies and Phenotype‐Specific Interaction With β‐Blockers in a Contemporary Population With Heart Failure},
  journal = {Journal of the American Heart Association},
  year = {2026},
  doi = {10.1161/jaha.125.047402}
}
Kostenlos starten →